- Comment to study: A randomized phase |III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild type (WT) KRAS metastatic colorectal cancer (mCRC) patients: German study AIO KRK-0306(FIRE-3)2013 | First Faculty of Medicine
- Treatment of metastatic colorectal carcinoma - 3rd line and abovePublication without faculty affiliation
- Case report: cetuximab in the 1st line of treatment of colorectal carcinoma2012 | Faculty of Medicine in Pilsen
- Rapid, deep and long lasting respnose to cetuximab2022 | Third Faculty of Medicine
- Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice2020 | Faculty of Physical Education and Sport, Faculty of Medicine in Pilsen, First Faculty of Medicine
- Safety and effectiveness of aflibercept + fluorouracil, leucovorin, and irinotecan (FOLFIRI) for the treatment of patients with metastatic colorectal cancer (mCRC) in current clinical practice: OZONE study2020 | Publication without faculty affiliation
- Prospective Observational Cohort Study to Describe the Use of Panitumumab in Combination with Chemotherapy in Real-World Clinical Practice for Patients with Wild-Type RAS mCRC2019 | First Faculty of Medicine
- Rechallenge with anti-EGFR therapy2023 | Third Faculty of Medicine
- Observed benefit and safety of aflibercept in elderly patients with metastatic colorectal cancer: An age-based analysis from the randomized placebo-controlled phase III VELOUR trial2018 | Publication without faculty affiliation
- A Randomized Phase III Trial Comparing Irinotecan (IRI) + 5FU/Folinic Acid (FA) to the Same Schedule of 5FU/FA in Patients (pts) with Metastatic Colorectal Cancer (MCRC) as Front Line Chemotherapy (CT)1999 | Publication without faculty affiliation
- Durable Complete Response of Colorectal Cancer Metastasis after Biochemotherapy2017 | Faculty of Physical Education and Sport, Faculty of Medicine in Pilsen, First Faculty of Medicine, Central Library of Charles University
- Bevacizumab in first-line therapy for metastatic colorectal cancer in combination with FOLFOX or XELOX2014 | First Faculty of Medicine
- Sarcopenia in Metastatic Colorectal Carcinoma2019 | Faculty of Physical Education and Sport, First Faculty of Medicine
- Panitumumab as first-line treatment of colorectal cancer2019 | Publication without faculty affiliation
- Panitumumab in the treatment of colorectal carcinoma2020 | Publication without faculty affiliation
- RAS mutation prevalence among patients with metastatic colorectal cancer: a meta-analysis of real-world data2017 | Central Library of Charles University
- Cost-effectiveness Analysis of Panitumumab Plus mFOLFOX6 Compared to Bevacizumab Plus mFOLFOX6 for First-line Treatment of Patients with Wild-type RAS Metastatic Colorectal Cancer - Czech Republic Model Adaptation2015 | Faculty of Medicine in Pilsen
- Sarcopenia and colorectal carcinoma2020 | First Faculty of Medicine
- Human MRCK alpha is regulated by cellular iron levels and interferes with transferrin iron uptake2010 | Faculty of Science, Faculty of Physical Education and Sport
- Human MRCK alpha is regulated by cellular iron levels and interferes with transferrin iron uptake2010 | First Faculty of Medicine
- Ultrasound and Clinical Preoperative Characteristics for Discrimination Between Ovarian Metastatic Colorectal Cancer and Primary Ovarian Cancer: A Case-Control Study2019 | Faculty of Physical Education and Sport, First Faculty of Medicine
- Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients2016 | First Faculty of Medicine, Central Library of Charles University, Faculty of Medicine in Hradec Králové
- MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab2015 | Publication without faculty affiliation
- Efficacy and safety of bevacizumab in elderly patients with metastatic colorectal cancer: results from the Czech population-based registry2014 | Faculty of Physical Education and Sport, First Faculty of Medicine, Second Faculty of Medicine
- Anti-angiogenic therapy for metastatic colorectal cancer - analysis of date from two centers2010 | First Faculty of Medicine
- Bevacizumab with FOLFIRI or XELIRI in the First-line Therapy of Metastatic Colorectal Carcinoma: Results from Czech Observational Registry2015 | Faculty of Medicine in Pilsen, First Faculty of Medicine
- Distant Metastasis in Colorectal Cancer Patients-Do We Have New Predicting Clinicopathological and Molecular Biomarkers? A Comprehensive Review2020 | Faculty of Physical Education and Sport, Faculty of Medicine in Pilsen, First Faculty of Medicine, Faculty of Medicine in Hradec Králové
- Novel predictive biomarker RAS: a crossroads or continuing the path taken?2013 | Faculty of Medicine in Pilsen
- Microsatellite Instability and Metastatic Colorectal Cancer - A Clinical Perspective2022 | First Faculty of Medicine
- Current view on the treatment of colorectal cancer2021 | Publication without faculty affiliation